Prescribing Information|Patient Tool Kit|Contact Us: tirvox@horizonpharma.com.pk
Tirvox

Clinical
Evidences

Browse peer-reviewed clinical and real-world studies detailing Tirzepatide treatment efficacy, metabolic outcomes, and patient safety profiles across major landmark trials.

Explore Publicationsarrow_downward
Clinical Evidences
biotechReal World Data
stethoscopeClinically Reviewed
verifiedPeer Reviewed
scienceEvidence Based
biotechReal World Data
stethoscopeClinically Reviewed
verifiedPeer Reviewed
scienceEvidence Based
biotechReal World Data
stethoscopeClinically Reviewed
verifiedPeer Reviewed
scienceEvidence Based
biotechReal World Data
stethoscopeClinically Reviewed
verifiedPeer Reviewed
scienceEvidence Based
biotechReal World Data
stethoscopeClinically Reviewed
verifiedPeer Reviewed
scienceEvidence Based
biotechReal World Data
stethoscopeClinically Reviewed
verifiedPeer Reviewed
scienceEvidence Based

Latest Research & Publications

auto_stories

Clinical Obesity (Wiley)

Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.12734

person
SURMOUNT-1 & SURMOUNT-4
View Research
auto_stories

ScienceDirect

Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies

https://www.sciencedirect.com/science/article/abs/pii/S1530891X25012923

person
Endocrine Practice
View Research
auto_stories

Journal of the Endocrine Society

Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome

https://academic.oup.com/jes/article/10/9/bvag177/8764203

person
PCOS & Weight Loss
View Research
auto_stories

JAMA Network

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

Jama, 327(6), 534-545

person
The SURPASS-5 Trial
View Research
auto_stories

HCPLive

Tirzepatide Use Can Slow Progression of CKD in Type 2 Diabetes

https://www.hcplive.com/view/tirzepatide-use-can-slow-progression-of-ckd-in-type-2-diabetes

person
Chronic Kidney Disease
View Research
auto_stories

PubMed

Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study

https://pubmed.ncbi.nlm.nih.gov/39949069/

person
Propensity Score-Matched Study
View Research
auto_stories

NEJM

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

https://www.nejm.org/doi/abs/10.1056/NEJMoa2401943

person
SYNERGY-NASH Trial
View Research
auto_stories

Diabetes Care (ADA)

Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials

Diabetes Care, 48(3), 430-436

person
SURPASS-1–5 Clinical Trials
View Research
auto_stories

AJRCCM

Measures Related to Obstructive Sleep Apnea After Tirzepatide Treatment by Baseline OSA Severity: Post-hoc Analyses of SURMOUNT-OSA

https://academic.oup.com/ajrccm/article/211/Supplement_1/A5207/8337296

person
SURMOUNT-OSA Trial
View Research
auto_stories

RMD Open (PMC)

If the evidence is there, why are GLP- 1 receptor agonists not on- label for hip and knee osteoarthritis in overweight patients?

https://pmc.ncbi.nlm.nih.gov/articles/PMC12458797/pdf/rmdopen-11-3.pdf

person
Osteoarthritis Evidence
View Research